Medicare Benefits Schedule (MBS) item changes starting 1 November 2021

Posted: 28th of October, 2021

The Government announced changes to the Medicare Benefits Schedule (MBS) in the 2021-22 Budget. These changes are the result of recommendations by either the Medical Services Advisory Committee or the MBS Review Taskforce, and will take effect on 1 November 2021.

Please refer to the following links for details regarding the MBS changes from 1 November 2021:

Pre-implantation Genetic Testing (PGT)

New MBS items for Allied Health Case Conferencing

Changes to MBS varicose vein items

Diagnostic imaging Medicare Benefits Schedule (MBS) item changes for 1 November 2021

Minor updates for Thoracic medicine items

Ambulatory blood pressure monitoring for diagnosis of hypertension

New MBS item for vertebroplasty

Expanded patient access to mastopexy (MBS item 45558)

Removal of age restriction for glucocorticoid injections of keloid lesions (MBS Item 30210)

Clarifying clinical intent of spinal decompression items (MBS items 51011 to 51015)

Autologous Fat Grafting

Clarifying the clinical intent of partial rhinoplasty (MBS item 45632)

Sentinel Lymph Node Biopsy (SLNBx) for intermediate thickness Melanoma

New Items – Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy

Minor changes to MBS Items for Orthopaedic Surgery

Endoscopic Mucosal Resection (EMR) from 1 November 2021

Further information on these changes is available now on MBS Online under the 'Factsheets' tab at

The Department of Health undertakes audits of MBS services to ensure correct billing. The department will be closely monitoring MBS data with regards to the 1 November 2021 changes and will refer any matters for compliance action if it becomes apparent that there is inappropriate claiming of MBS items.

If you require further information on the implementation of these changes please email: [email protected].